The Johns Hopkins Bloomberg School of Public Health has been awarded $18.4 million by the Orthopaedic Extremity Trauma Research Program (OETRP) of the U.S. Department of Defense to establish an Extremity Trauma Clinical Research Consortium. The Bloomberg School will serve as the coordinating center for the Consortium that includes a network of twelve core civilian trauma centers working together with several major military treatment centers and the U.S. Army Institute of Surgical Research (USAISR) at Fort Sam Houston, Texas.
The overarching goal of the Consortium is to conduct multi-center clinical research studies relevant to the treatment and outcomes of severe orthopaedic trauma sustained on the battlefield. These studies will help establish treatment guidelines and facilitate the translation of new and emerging technologies into clinical practice.
"The need for such a consortium is evident," said Ellen MacKenzie, PhD, principal investigator and the Fred and Julie Soper Professor and Chair of the Bloomberg School's Department of Health Policy and Management. "Eighty-two percent of all service members injured in Operation Iraqi Freedom and Operation Enduring Freedom sustain extremity trauma. Many sustain injuries to multiple limbs. The research to be conducted by the Consortium will help us better understand what works and what doesn't in treating these injuries and ensure that our service members are provided with the best care possible."
Initial funding of the consortium will help establish the network and provide the resources to address some of the critical needs in acute clinical care identified by the military. These include the reconstruction of significant bone defects and the management of musculoskeletal infections. Over time it will expand and leverage its infrastructure to address many other priority topics relevant to the long-term management of severe extremity trauma, including the prevention of osteomyelitis, chronic pain and disability.
"The Consortium is committed to conducting high quality clinical research that will make a difference in the lives of those who sustain severe limb injuries," said Dr. Michael Bosse of Carolinas Medical Center, Chair of the Consortium and co-principal investigator with Dr. MacKenzie. "It will do so by establishing a clinical research network that is dynamic and responsive to new clinical challenges and the emergence of new, promising novel therapies."
An important feature of the Consortium will be its ability to expand the number of clinical sites participating in any one clinical study. Over 30 trauma centers around the country have pledged support for the Consortium and are eager to participate in one or more of the studies sponsored under its umbrella.